share_log

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

Why Is Depression-Focused Sage Therapeutics Stock Surging Higher On Monday?

爲什麼以抑鬱症爲重點的Sage Therapeutics股票在週一大幅上漲?
Benzinga ·  01/13 14:38

On Friday, Sage Therapeutics Inc. (NASDAQ:SAGE) confirmed that Biogen Inc. (NASDAQ:BIIB) submitted an unsolicited, nonbinding proposal to acquire all of the outstanding shares of Sage Therapeutics not already owned by Biogen for $7.22 per share.

週五,Sage Therapeutics Inc.(納斯達克:SAGE)確認,渤健公司(納斯達克:BIIB)提交了一份非正式、非約束性的收購提案,擬以每股7.22美元收購渤健尚未擁有的所有Sage Therapeutics的流通股份。

The Sage Board of Directors will carefully review and evaluate Biogen's proposal.

Sage董事會將仔細審查和評估渤健的提案。

Also Read: After Failed Alzheimer's Study, Sage Therapeutics' Dalzanemdor Flunks Another Study In Patients With Inherited Brain Disorder

另請閱讀:在阿爾茨海默病研究失敗後,Sage Therapeutics的Dalzanemdor在遺傳性腦部疾病患者中再次失敗。

In November 2020, Biogen and Sage Therapeutics executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.

在2020年11月,渤健公司與Sage Therapeutics簽署了一項全球合作與許可協議,共同開發和商業化zuranolone(SAGE-217)用於主要抑鬱症(MDD)、產後抑鬱症(PPD)及其他精神疾病,以及SAGE-324用於重要性震顫及其他神經系統疾病。

The deal included an upfront payment of $875 million and a $650 million equity investment. Sage was also eligible to receive up to approximately $1.6 billion in potential milestone payments.

該交易包括87500萬美元的預付款和65000萬美元的股權投資。Sage還有資格獲得最多約16億美元的潛在里程碑支付。

Over the last five years, Sage stock has slumped 90%.

在過去五年中,Sage的股價已經下跌了90%。

In October last year, Sage Therapeutics announced a strategic reorganization of its business operations to support the ongoing launch of Zurzuvae (zuranolone) in postpartum depression.

去年十月,Sage Therapeutics宣佈對其業務運營進行戰略重組,以支持Zurzuvae(zuranolone)在產後抑鬱症中的持續推出。

The company said the reorganization was intended to strengthen Sage's balance sheet, extend its cash runway, and position the company for long-term growth potential.

該公司表示,重組旨在增強Sage的資產負債表,延長其現金儲備,併爲公司長期增長潛力奠定基礎。

The company's layoff impacted over 165 employees (approximately 33% of its total workforce and approximately 55% of its R&D workforce), including changes to the leadership team.

公司的裁員影響了超過165名員工(約佔總員工人數的33%和研發團隊的約55%),包括領導團隊的變動。

In September, Biogen terminated its rights under the collaboration and license agreement with Sage, which was specific to the SAGE-324 program.

渤健公司在九月份終止了與Sage的合作和許可協議下的權利,該協議專門針對SAGE-324項目。

Price Action: SAGE stock is up 37.3% at $7.62, and BIIB stock is down 0.25% at $148.45 at last check Monday.

價格走勢:SAGE股票上漲37.3%,報$7.62,而BIIb股票下跌0.25%,報$148.45,最後一次檢查是週一。

  • Asia And Europe Markets Fall, Dollar Hits New High – Global Markets Today While US Slept
  • 亞洲和歐洲市場下跌,美元創下新高——全球市場今日在美國沉睡時。

Image via Shutterstock.

圖片由Shutterstock提供。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。